IQVIA Holdings Inc. (NYSE:IQV), a global leader in advanced analytics, technology solutions, and clinical research services for the healthcare and life sciences industries, finds itself at a critical ...
Shares of IQVIA Holdings Inc. IQV slipped 1.12% to $199.11 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,994.57 ...
US biosimilar 'void' spells trouble as biologic patent expirations loom, IQVIA report says
While 118 biologics are expected to lose patent protection in the US over the next decade, that $234 billion opportunity for ...
In Part 7 – the final instalment of our inaugural Life Sciences Industry Report – we look more closely at reporting from 2024 ...
Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...
Gland Pharma on Monday reported 7% year-on-year (YoY) rise in net profit to Rs 205 crores in Q3FY25. The company reported net ...
Drug maker Alembic Pharma on Monday reported Rs 138 crore net profit in Q3FY25, which is 23% year-on-year (YoY) decline ...
Overall the Q4 earnings season continues to come in better-than-expected. That has thrust quarterly growth to 13.2% according ...
Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...
Digital health is revolutionising healthcare through modern technologies, helping us bridge gaps that once seemed ...
Over the past year, many IQVIA Holdings Inc. ( NYSE:IQV ) insiders sold a significant stake in the company which ...
BTIG analyst David Larsen adjusted the firm's stance on IQVIA Holdings (NYSE:IQV), moving from a Buy rating to Neutral. The $36.5 billion market cap company, currently trading near its 52-week low at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback